Boehringer Ingelheim Press Release


Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies
Jun 02, 2022 21:00 JST

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies
Jun 02, 2022 21:00 JST
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.
More info..

Latest Release


More Latest Release >>